Although the aberrant activation of KP and expression patterns of the first rate-limiting KP enzyme in gliomas have been previously reported,5,9,10,13,31–34 the systemic and comprehensive studies of the expression, activity, and individual function of IDO1 and its isozymes in gliomas are very limited. This evidence concerns the gene IDO1 and central nervous system cancer.